MIM
TXG icon

MetLife Investment Management’s 10x Genomics TXG Stock Holding History

MetLife Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Buy
69,381
+5,591
+9% +$147K 0.01% 979
2026
Q1 		$1.35M Buy
63,790
+619
+1% +$12.4K 0.01% 1261
2025
Q4 		$1.03M Hold
63,171
– – 0.01% 1414
2025
Q3 		$738K Hold
63,171
– – ﹤0.01% 1617
2025
Q2 		$732K Buy
63,171
+58,204
+1,172% +$531K ﹤0.01% 1480
2025
Q1 		$43.4K Buy
4,967
+4
+0.1% +$50 ﹤0.01% 2701
2024
Q4 		$71.3K Sell
4,963
-33
-0.7% -$521 ﹤0.01% 2707
2024
Q3 		$113K Sell
4,996
-100
-2% -$2.07K ﹤0.01% 2578
2024
Q2 		$99.1K Sell
5,096
-486
-9% -$12.7K ﹤0.01% 2609
2024
Q1 		$209K Buy
5,582
+17
+0.3% +$747 ﹤0.01% 2181
2023
Q4 		$311K Sell
5,565
-77
-1% -$3.35K ﹤0.01% 1971
2023
Q3 		$233K Buy
5,642
+3
+0.1% +$156 ﹤0.01% 2117
2023
Q2 		$315K Buy
5,639
+445
+9% +$24.1K ﹤0.01% 1982
2023
Q1 		$290K Buy
5,194
+13
+0.3% +$607 ﹤0.01% 1987
2022
Q4 		$189K Sell
5,181
-130
-2% -$4.25K ﹤0.01% 2280
2022
Q3 		$151K Buy
5,311
+61
+1% +$2.32K ﹤0.01% 2458
2022
Q2 		$238K Sell
5,250
-220
-4% -$11.4K ﹤0.01% 2193
2022
Q1 		$416K Buy
+5,470
New +$479K ﹤0.01% 1888
2021
Q2 		– Sell
-3,886
Closed -$703K – 2487
2021
Q1 		$703K Buy
+3,886
New +$671K 0.01% 1329
2020
Q4 		– Sell
-4,918
Closed -$613K – 2311
2020
Q3 		$613K Buy
+4,918
New +$516K 0.01% 1265

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MetLife Investment Management's TXG Position: Q2 2026 in Review

MetLife Investment Management increased its 10x Genomics (TXG) stake by 8.8% in Q2 2026, buying an estimated $147K and bringing the position to 69,381 shares worth $2.66M. The position accounts for 0.01% of the portfolio, ranked #979.

MetLife Investment Management first reported a position in TXG in Q3 2020 and has held it in 20 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • MetLife Investment Management held 69,381 shares of 10x Genomics worth $2.66M as of Q2 2026.
  • MetLife Investment Management bought 5,591 10x Genomics shares in Q2 2026, an estimated $147K.
  • 10x Genomics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #979 holding.
  • MetLife Investment Management first reported a position in 10x Genomics in Q3 2020 and has held it in 20 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.